Raymond James Financial Services Advisors, Inc. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.

Quarter-by-quarter ownership
Raymond James Financial Services Advisors, Inc. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2021$34,000
-5.6%
13,961
-2.8%
0.00%
Q3 2021$36,000
-12.2%
14,361
-0.0%
0.00%
Q2 2021$41,000
+24.2%
14,363
+2.9%
0.00%
Q1 2021$33,000
+57.1%
13,961
+15.6%
0.00%
Q4 2020$21,000
+50.0%
12,075
-19.8%
0.00%
Q3 2020$14,0000.0%15,060
-7.1%
0.00%
Q2 2020$14,000
-22.2%
16,204
-18.4%
0.00%
Q4 2019$18,000
-57.1%
19,860
-53.4%
0.00%
Q3 2019$42,00042,6410.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders